Research Analysts Set Expectations for Liquidia Q2 Earnings

Liquidia Co. (NASDAQ:LQDA - Free Report) - Equities researchers at Lifesci Capital issued their Q2 2025 earnings per share (EPS) estimates for Liquidia in a report released on Wednesday, March 19th. Lifesci Capital analyst C. Jubinville forecasts that the company will post earnings of ($0.35) per share for the quarter. The consensus estimate for Liquidia's current full-year earnings is ($1.51) per share. Lifesci Capital also issued estimates for Liquidia's Q3 2025 earnings at ($0.39) EPS, Q4 2025 earnings at ($0.31) EPS and FY2025 earnings at ($1.41) EPS.

Liquidia (NASDAQ:LQDA - Get Free Report) last released its quarterly earnings results on Wednesday, March 19th. The company reported ($0.46) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.38) by ($0.08). Liquidia had a negative net margin of 765.38% and a negative return on equity of 163.21%. The firm had revenue of $2.92 million during the quarter, compared to the consensus estimate of $4.60 million.

Several other analysts have also recently weighed in on the stock. Wells Fargo & Company assumed coverage on shares of Liquidia in a research note on Friday, December 20th. They issued an "overweight" rating and a $20.00 price objective for the company. Scotiabank restated an "outperform" rating on shares of Liquidia in a research note on Thursday, March 20th. Needham & Company LLC lifted their price objective on Liquidia from $19.00 to $25.00 and gave the company a "buy" rating in a report on Thursday, March 20th. Finally, HC Wainwright restated a "buy" rating and issued a $29.00 price target on shares of Liquidia in a research report on Thursday, March 20th. One equities research analyst has rated the stock with a hold rating, six have assigned a buy rating and two have assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the company has an average rating of "Buy" and a consensus target price of $26.63.

Remove Ads

Liquidia Stock Down 4.7 %

Shares of Liquidia stock traded down $0.73 during trading on Monday, reaching $14.87. The company's stock had a trading volume of 630,004 shares, compared to its average volume of 931,780. The business's 50-day moving average price is $14.95 and its 200-day moving average price is $12.32. Liquidia has a 52 week low of $8.26 and a 52 week high of $16.81. The firm has a market cap of $1.27 billion, a PE ratio of -9.12 and a beta of 0.07.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in the business. Intech Investment Management LLC bought a new position in shares of Liquidia during the third quarter valued at $195,000. Charles Schwab Investment Management Inc. increased its holdings in Liquidia by 144.8% in the third quarter. Charles Schwab Investment Management Inc. now owns 390,257 shares of the company's stock valued at $3,903,000 after purchasing an additional 230,820 shares during the period. BNP Paribas Financial Markets raised its position in Liquidia by 735.1% during the 3rd quarter. BNP Paribas Financial Markets now owns 140,190 shares of the company's stock worth $1,402,000 after purchasing an additional 123,402 shares during the last quarter. Acuta Capital Partners LLC bought a new position in Liquidia during the 3rd quarter worth $735,000. Finally, Zurcher Kantonalbank Zurich Cantonalbank lifted its holdings in Liquidia by 43.5% during the 3rd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 18,708 shares of the company's stock worth $187,000 after buying an additional 5,669 shares during the period. Institutional investors own 64.54% of the company's stock.

Insider Activity

In related news, insider Rajeev Saggar sold 6,249 shares of Liquidia stock in a transaction that occurred on Tuesday, January 14th. The shares were sold at an average price of $11.78, for a total transaction of $73,613.22. Following the sale, the insider now directly owns 270,388 shares of the company's stock, valued at approximately $3,185,170.64. The trade was a 2.26 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CFO Michael Kaseta sold 23,370 shares of the stock in a transaction that occurred on Tuesday, January 14th. The shares were sold at an average price of $11.78, for a total transaction of $275,298.60. Following the completion of the transaction, the chief financial officer now directly owns 401,755 shares of the company's stock, valued at approximately $4,732,673.90. The trade was a 5.50 % decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders have sold 71,245 shares of company stock worth $843,326. Insiders own 30.10% of the company's stock.

Liquidia Company Profile

Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).